Oncodesign Announces Drug Discovery Cooperation With ViraTherapeutics, a Boehringer Ingelheim Subsidiary
03 Novembre 2020 - 6:00PM
Business Wire
Agreement to support preclinical investigation
of novel viral based immunotherapies for the treatment of
cancer
Regulatory News:
ONCODESIGN (ALONC – FR0011766229) (Paris:ALONC), a
biopharmaceutical group specialized in precision medicine,
announced today the signature of a new multi-year service agreement
(DDSA1) with ViraTherapeutics, a subsidiary of Boehringer Ingelheim
based in Innsbruck (Austria) and specialized in oncolytic viral
immunotherapy2.
Under this agreement, Oncodesign will play a key role for
Austrian biotech company ViraTherapeutics, handling the preclinical
assessment of its immunotherapy programs, which aim to develop
next-generation vesicular stomatitis virus (VSV-GP) variants in
immuno-oncology.
This two-year partnership deal falls within Oncodesign’s
development strategy of supporting pharmaceutical and biotech
companies during the early development stages of their therapeutic
innovations under global strategic alliances.
“We are delighted that we will be working together under this
agreement with ViraTherapeutics, a leading innovator in the
development of oncolytic viral therapies and part of Boehringer
Ingelheim. We are thrilled to be playing our part in their various
ground-breaking oncology programs”, commented Fabrice Viviani,
Managing Director and Head of the Oncodesign Services Business
Unit.
“We are proud that ViraTherapeutics chose us as a key partner
for conducting its oncolytic virus assessments. This partnership
once again confirms the relevance and interest of the industry for
our DDSA service offering. It is a tremendous encouragement to
consolidate our efforts to put in place strategic agreements with
innovative biotech companies and leading decision-makers in the
pharmaceutical industry, in order to bring new therapeutic
solutions to market as fast as possible to improve patient
treatments and meet the strong therapeutic demand in oncology and
infectious diseases”, added Philippe Genne, Chairman,
Chief Executive Officer and Founder of Oncodesign.
About Oncodesign: www.oncodesign.com
Founded 25 years ago by Dr. Philippe Genne, the Company’s CEO
and Chairman, Oncodesign is a biopharmaceutical company dedicated
to precision medicine. With its unique experience acquired by
working with more than 800 clients, including the world’s largest
pharmaceutical companies, along with its comprehensive
technological platform combining state-of-the-art medicinal
chemistry, pharmacology, regulated bioanalysis, medical imaging and
Artificial Intelligence, Oncodesign is able to predict and
identify, at a very early stage, each molecule's therapeutic
usefulness and potential to become an effective drug. Applied to
kinase inhibitors, which represent a market estimated at over $65
billion by 2027 and accounting for almost 25% of the pharmaceutical
industry’s R&D expenditure, Oncodesign’s technology has already
enabled the targeting of several promising molecules with
substantial therapeutic potential, in oncology and elsewhere, along
with partnerships with pharmaceutical groups such as Servier.
Oncodesign is based in Dijon, France, in the heart of the town’s
university and hospital hub, and within the Paris-Saclay cluster.
Oncodesign has 233 employees and subsidiaries in Canada and the
USA.
Disclaimer
This press release contains certain forward - looking statements
and estimates concerning the Company’s financial condition,
operating results, strategy, projects and future performance and
the markets in which it operates. Such forward-looking statements
and estimates may be identified by words such as “anticipate,”
“believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is
designed to,” “may,” “might,” “plan,” “potential,” “predict,”
“objective,” “should,” or the negative of these and similar
expressions. They incorporate all topics that are not historical
facts. Forward looking statements, forecasts and estimates are
based on management’s current assumptions and assessment of risks,
uncertainties and other factors, known and unknown, which were
deemed to be reasonable at the time they were made but which may
turn out to be incorrect. Events and outcomes are difficult to
predict and depend on factors beyond the Company’s control.
Consequently, the actual results, financial condition, performances
and/or achievements of the Company or of the industry may turn out
to differ materially from the future results, performances or
achievements expressed or implied by these statements, forecasts
and estimates. Owing to these uncertainties, no representation is
made as to the correctness or fairness of these forward-looking
statements, forecasts and estimates. Furthermore, forward-looking
statements, forecasts and estimates speak only as of the date on
which they are made, and the Company undertakes no obligation to
update or revise any of them, whether as a result of new
information, future events or otherwise, except as required by
law.
1 Drug Discovery Strategic Alliance 2 Oncolytic viral therapies
use a virus designed to infect and replicate specifically in cancer
cells, destroying those cells but leaving healthy cells
untouched
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201103005447/en/
Oncodesign Philippe Genne Chairman and CEO Tél.: +33 (0)3
80 78 82 60 investisseurs@oncodesign.com
NewCap Investor Relations Mathilde Bohin / Louis-Victor
Delouvrier Tél.: +33 (0)1 44 71 94 95 oncodesign@newcap.eu
NewCap Media Relations Arthur Rouillé Tél.: +33 (0)1 44
71 00 15 oncodesign@newcap.eu